Spencer, Andrew <br/><br/>
Daratumumab plus bortezomib and dexamethasone   [electronic resource] 

 -  Haematologica  12 2018 
 - 2079-2087 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Standard No.: </label>10.3324/haematol.2018.194118  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bortezomib--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Drug Resistance, Neoplasm<br/>Follow-Up Studies<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Neoplasm Recurrence, Local<br/>Neoplasm, Residual--diagnosis<br/>Outcome Assessment, Health Care--methods